February 11, 2019 08:46 AM EST

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

Natalie Grover

Reporter

Arcturus Therapeutics had a melodramatic 2018 — the San Diego biotech’s CEO Joseph Payne was asked to leave for putting his interests before the RNA company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

Natalie Grover

Reporter

Sign up to read this article for free.

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Cure­Vac walks away from Arc­turus' urea cy­cle dis­or­der drug, but part­ner­ship re­mains in­tact

Natalie Grover

Reporter

Sign up to read this article for free.

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?